The Pharma Data

NOVEMBER 4, 2020

TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

NOVEMBER 16, 2020

“Fat contains cells with the intrinsic capacity of healing: the strength to mend scaffolds, bleeding vessels, and extinguish inflammation within the tissues,” says Dr. Llull. The Panel discussion recorded on October 1, 2020, features Dr. Alexander and Dr. Ramon Llull, MD, Ph.D.,

Trials 52

Trials Clinical Trials Clinical Trials Dermatology 52

The Pharma Data

OCTOBER 27, 2020

Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.

HR 40

HR Dermatology Marketing Production 40

The Pharma Data

JANUARY 12, 2021

Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

Cloudbyz

AUGUST 7, 2024

In this blog we delve into how past economic downturns influenced the clinical trials market, look at statistics and insights of therapeutic areas and funding trends, and pinpoint how central technology can be in overcoming the challenge. Investments on research of cancer continued while the oncology trials gained 5%.

Clinical Research 52

Clinical Research Clinical Trials Clinical Trials Research 52

XTalks

SEPTEMBER 5, 2024

” Opzelura (ruxolitinib), which contains 1.5 As the camera shifts to the commercial on the TV, a young person, portrayed by producer and actress Kristen Vaganos , asks the viewers to imagine finding a steroid-free cream for mild to moderate eczema that targets inflammation, gives clear skin and “kicks the itch.”

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Containment 52

The Pharma Data

JANUARY 13, 2021

(IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases. More information is available on the Company website at www.IPharmInc.com.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vitro 52

The Pharma Data

MAY 18, 2021

Our Crop Science Division achieved encouraging sales growth in an improved market environment. This business also expanded in Asia/Pacific as the market situation normalized following the previous year’s restrictions related to the COVID-19 pandemic. to 1.252 billion euros in a declining market. percent (Fx & portfolio adj.)

Sales 40

Sales Production Marketing Containment 40

The Pharma Data

NOVEMBER 4, 2020

Initial data from an ongoing long-term, open label extension study with CTP-543 were presented in the late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 29, 2020. Published Findings on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Dermatology 52

The Pharma Data

DECEMBER 15, 2020

Klisyri will be manufactured by Athenex, highlighting the vertically integrated capabilities of the company ranging from a preclinical lead to a developed product for market launch. Mr. Peter Guenter, CEO of Almirall, stated, “We are delighted to partner with Athenex to market Klisyri in the U.S. during the first quarter of 2021.

FDA Approval 52

FDA Approval Development Production Drugs 52

The Pharma Data

JULY 11, 2021

Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin in Berlin, Germany. Depending on regional marketing authorization, TAKHZYRO is available as a 300 mg dose in a vial or pre-filled syringe. Markus Magerl, M.D., TAKHZYRO is not intended for treatment of acute HAE attacks. Interactions.

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 52

Production Dermatology Development Containment 52

The Pharma Data

FEBRUARY 22, 2022

Next-generation respiratory inhalers Most patients with asthma and chronic obstructive pulmonary disease (COPD) need inhaled medicines 2 and many make use of pressurised metered dose inhalers (pMDIs) 2 which contain small quantities of a type of GHG which acts as the propellant to deliver the medicine into the lungs.

Development 52

Development Medicine Containment Dermatology 52

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 40

Production Dermatology Development Containment 40

The Pharma Data

OCTOBER 26, 2020

The European Medicines Agency (EMA) has also accepted the Marketing Authorization Application (MAA) for abrocitinib in the same patient population with a decision anticipated in the second half of 2021. DISCLOSURE NOTICE: The information contained in this release is as of October 27, 2020. Dermatology. 1 Hanifin JM, Reed ML.

Clinical Trials 40

Clinical Trials Clinical Trials Medicine Trials 40

The Pharma Data

APRIL 28, 2021

These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14. IR main line: Tel.: +33

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

The Pharma Data

JULY 23, 2021

We took this action following the Agency’s industry-wide evaluation of accelerated approvals for checkpoint inhibitors that have not met their post-marketing requirements demonstrating confirmatory benefit. endocrinopathies and dermatologic reactions) are discussed below.

Hormones 52

Hormones Trials Genome Genomics 52

Delveinsight

AUGUST 13, 2020

It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, a long-acting beta2-adrenergic agonist, delivered in GSK’s Ellipta dry powder inhaler. REGN3500 is being studied in Phase II trials for asthma, chronic obstructive pulmonary disease and atopic dermatitis.

Antibody 40

Antibody Medicine Trials Development 40

The Pharma Data

AUGUST 11, 2020

OPDIVO ® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

OPDIVO ® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

Pfizer

JANUARY 27, 2023

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Disclosure Notice The information contained in this statement is as of January [30], 2023.

Bacteria 75

Bacteria Medicine Containment Manufacturing 75

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. INDIANAPOLIS , Oct.

Dermatology 52

Dermatology Development Medicine Clinical Trials 52

The Pharma Data

SEPTEMBER 15, 2020

The Inflammation & Immunology pipeline is focused on patients with autoimmune and chronic inflammatory diseases across rheumatology, gastroenterology and dermatology, with five distinct immuno-kinases, in oral and topical formulations, studied for potential treatment of 10 diseases, and three additional novel biologics in Phase 2 studies.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

XTalks

DECEMBER 20, 2023

Novo Nordisk’s GLP-1 weight loss-specific drug Wegovy (semaglutide) has been facing similar shortages, as it contains the same active ingredient as Ozempic. The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. It contains the antiviral medications nirmatrelvir and ritonavir.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JANUARY 26, 2021

Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.

Life Science 40

Life Science Production Marketing Dermatology 40

The Pharma Data

APRIL 26, 2021

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. USD 789 million, +34% cc) sustained strong growth with increased patient share across markets, driven by demand as the essential first choice therapy for heart failure patients.

Sales 40

Sales Medicine Production Manufacturing 40

Pfizer

OCTOBER 28, 2022

PRAC’s recommendation follows a review of available data, including the final results of ORAL Surveillance (A3921133; NCT02092467), a post-marketing required tofacitinib safety study in rheumatoid arthritis (RA) patients, and on preliminary results for the JAK inhibitor, baricitinib, from the observational retrospective Study I4V-MC-B023 (B023).

Clinical Trials 40

Clinical Trials Clinical Trials Vaccination Vaccine 40

XTalks

DECEMBER 24, 2024

The 60-second ad features two children sitting together at lunch, as a voiceover explains that while one box contains a peanut lovers favorite, the other holds sunflower butter, thoughtfully packed by a parent for their child. billion TV impressions and an estimated ad spend of $20.4 during US Open ENCORE on December 4, 2024.

Drugs 105

Drugs Allergies Vaccination Vaccine 105